Collaboration and License Agreements (Tables)

6 Months Ended

Sep. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Collaboration and License Agreements

The following table presents changes in the Company’s contract liabilities during the six months ended September 30, 2021 (in thousands):

	Balance at March 31, 2021		Additions		Imputed Interest		Deductions		Balance at September 30, 2021
Contract liabilities:
Deferred revenue (1)	$	497,933	$	100,000	$	—	$	(71,348)	$	526,585
Cost share advance from Pfizer (2)	$	121,862	$	—	$	1,210	$	(38,304)	$	84,768

(1) Includes $100.6 million and $426.0 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of September 30, 2021. Includes $100.6 million and $397.4 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2021.

(2) Includes $84.8 million presented as current on the unaudited condensed consolidated balance sheet as of September 30, 2021. Includes $92.4 million and $29.4 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2021.